Premium
Postoperative UFT Adjuvant and the Risk Factors for Recurrence in Renal Cell Carcinoma: A Long‐Term Follow‐Up Study
Author(s) -
Naito Seiji,
Kumazawa Joichi,
Omoto Tetsuo,
Iguchi Atsushi,
Sagiyama Kazuyuki,
Osada Yukio,
Hiratsuka Yoshiharu
Publication year - 1997
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1997.tb00130.x
Subject(s) - medicine , nephrectomy , renal cell carcinoma , tegafur , adjuvant , adjuvant therapy , stage (stratigraphy) , urology , surgery , carcinoma , gastroenterology , oncology , kidney , chemotherapy , paleontology , biology
Background Radical nephrectomy is the standard therapy for low‐stage renal cell carcinoma. However, recurrence sometimes develops even in patients who are considered to have undergone a curative resection of the primary tumor. The purpose of this study was to evaluate the usefulness of UFT (a 1: 4 mixture of tegafur and uracil) adjuvant and the risk factors for recurrence in renal cell carcinoma. Methods A prospective randomized trial was conducted to compare the use of long‐term oral UFT adjuvant with nonadjuvant therapy after a radical nephrectomy for Robson stage I or II renal cell carcinoma. A multivariate analysis was also performed to estimate the risk factors for recurrence. Results A total of 71 patients were entered into this study, and 66 were evaluable (33 for each group). There was no significant difference in patient characteristics between the 2 groups. The nonrecurrence rate at 5 years after a radical nephrectomy was 80.5% and 77.1% in the UFT adjuvant group and the nonadjuvant group, respectively, with a median follow‐up of 112.9 months; the difference was not significant. The toxicity of UFT was generally mild and tolerable. The tumor grade was found to be an important factor influencing recurrence. Conclusion UFT cannot be universally recommended as an adjuvant therapy for radical nephrectomy in all patients with low‐stage renal cell carcinoma.